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Abstract: Carcinomatous encephalitis is a rapidly fatal form of metastasis caused by miliary 
spread of systemic cancer into the brain parenchyma. The diagnostic criteria and optimal treat-
ment for this disease are not well deﬁ  ned. We report a patient with rapid neurologic deterioration 
from carcinomatous encephalitis from lung adenocarcinoma. She was treated with geﬁ  tinib and 
high-dose fractionated whole brain radiotherapy, and eventually improved neurologically and was 
discharged home on hospital day 48. Geﬁ  tinib and high-dose fractionated radiotherapy may have 
synergistic activity in patients with carcinomatous encephalitis from non-small cell lung cancer 
having favorable prognostic factors. More importantly, timely recognition of this disease and the 
use of large fraction radiation therapy are necessary to control rapid neurologic deterioration.
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Introduction
Widespread cerebral metastases manifesting in a miliary pattern are known as “carcino-
matous encephalitis” or “miliary metastases” (Madow and Alper 1951). This condition 
is seldom reported because of rapid patient demise and poor visualization on head 
CT or MRI due to microscopic metastases that have not yet developed tumor 
vasculature (Madow and Alper 1951; Nemzek et al 1993; Shirai et al 1997; McGuigan 
et al 2005). But as these tumors increase in size, enhancement would appear due to 
tumor angiogenesis (Hanahan and Weinberg 2000; Folkman 2002) and concurrent 
subarachnoid spread is possible. Although whole brain radiation is the standard 
treatment for brain metastases, there have been no reported cases to our knowledge 
describing a clinical response. We report here a patient with rapid neurologic dete-
rioration from carcinomatous encephalitis from non-small cell lung cancer that was 
reversed by geﬁ  tinib and high-dose fractionated whole brain radiation, resulting in 
clinical improvement in cognition, resolution of tonsillar herniation and reversal of 
limb posturing and eye movement abnormalities.
Case report
A 39-year-old Chinese woman, non-smoker, experienced a 2-week history of progres-
sive holocranial headaches, disorientation to time and place, dressing apraxia, and 
low back pain. Gadolinium-enhanced head MRI showed multiple hemorrhagic and 
ring-enhancing lesions in bilateral cerebral and cerebellar hemispheres (Figures 1a 
and 1b), accompanied by mild edema without obstructive hydrocephalus or herniation. 
She received dexamethasone 24 mg daily and was transferred to our hospital 2 days 
later. A body CT demonstrated a large mass in the upper lobe of left lung, as well 
as multiple enhancements in the liver and lumbar vertebral bodies without epidural 
disease. Her respective CEA and LDH levels were rapidly rising to 69 ng/ml and Biologics: Targets & Therapy 2007:1(3) 322
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1,457 units/l. Biopsy of a liver lesion demonstrated adenocar-
cinoma, suggesting stage IV non-small cell lung carcinoma. 
On hospitalization day 8, she received carboplatin (AUC 
6) and paclitaxel (200 mg/m2) and experienced increasing 
headaches and vomiting. On day 11, after receiving 1 mg 
lorazepam and 20 mg dexamethasone prior to whole brain 
radiation, she became unresponsive and had left-arm ﬂ  exor 
posturing. Her radiation was withheld. She received 0.2 mg 
intravenous ﬂ  umazenil, 10 mg dexamethasone, and 1,000 
mg phenytoin without improvement. A head CT showed 
increased cerebral edema with tonsillar herniation. Following 
intravenous mannitol, an intraventricular drain was placed 
at bedside. Her left arm ﬂ  exor posturing resolved but she 
remained minimally responsive to verbal commands; she also 
had downbeat nystagmus and right conjugate eye deviation. 
On day 12, she began whole brain radiation with daily doses 
of 400 cGy for 5 days to a total dose of 2,000 cGy. On day 
13, she started geﬁ  tinib at 250 mg daily and her phenytoin 
was switched to levetiracetam, a non-P450-enzyme-inducing 
anticonvulsant. By day 17, she became alert, appropriately 
responsive to verbal commands, and conversing in 2- to 
3-word sentences. She had conjugate deviation of both eyes 
to the left on command. On day 30, CSF from her ventricular 
drain showed 5 WBC, 15 mg/dL protein, 121 mg/dL glucose, 
positive cytology for malignant cells, and positive for cultures 
for coagulase-negative Staphylococcus. She was treated with 
intrathecal and intravenous vancomycin. After 7 days of 
negative CSF cultures, she underwent ventriculoperitoneal 
shunt placement. Her respective CEA and LDH dropped to 
22 ng/mL and 419 units/L. She was discharged home on 
day 48 on geﬁ  tinib and levetiracetam, and later followed up 
in our ambulatory clinic. Two months after discharge, she 
returned to work part-time and ambulated with a cane. A 
repeat gadolinium-enhanced head MRI on day 68 showed 
near complete resolution of brain metastases (Figures 2a 
and 2b). But her liver and vertebral metastases only had a 
partial response.
Discussion
The metastases in our patient were located deep in the brain 
parenchyma and at the gray-white matter junction pointing 
to hematogeneous spread of her lung adenocarcinoma. Her 
rapid neurologic deterioration associated with diffuse cerebral 
edema suggests that there were more metastases than could 
be visualized on MRI, indicating carcinomatous encephalitis 
as the likely diagnosis. However, the diagnostic criteria for 
this disease are poorly deﬁ  ned but clinicians often based 
their diagnosis on the presence of multiple non-enhancing 
parenchymal brain metastases in a miliary pattern as key 
ﬁ  ndings. Such a narrowly deﬁ  ned criterion has limitations, 
and it does not incorporate clinical data and our understanding 
of tumor biology. First, gadolinium enhancement probably 
occurs when a tumor reaches a size large enough to promote 
angiogenesis (Folkman 2002). Although miliary tumors in 
carcinomatous encephalitis are non-enhancing initially, they 
would enhance eventually on MRI as they grow over time. 
Figure 1 Day 4 axial post-gadolinium T1-weighted MRI prior to whole brain radiation, demonstrating multiple small enhancing lesions throughout brain parenchyma (a) and (b).
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Second, rapid generalized neurologic deterioration is common 
in these patients. Lastly, given the rapid tumor progression, 
tumor cell inﬁ  ltration into the subarachnoid space could be a 
natural progression of carcinomatous encephalitis.
In the United States, whole brain cranial irradiation at 
300 cGy per fraction × 10 fractions is the standard treatment 
for patients with brain metastases, particularly for those 
patients with poor performance status. However, due to her 
rapid neurological deterioration, our patient needed a radia-
tion schedule that would offer the quickest response. Borgelt 
et al (1980) compared four treatment regimens, 200 cGy × 20, 
250 cGy × 15, 200 cGy × 15, and 300 cGy × 10, and noted 
equivalent clinical radiobiological efﬁ  cacy. We chose a 
high-dose fractionated schedule of 400 cGy × 5 (Borgelt 
1981) to achieve rapid tumor response and neurological 
improvement.
Geﬁ  tinib is a small molecule tyrosine kinase inhibitor 
of epidermal growth factor receptor (EGFR) that produced 
dramatic radiologic and clinical responses in 10% of patients 
with non-small cell lung cancer (Kris 2003). Female gender, 
non-smokers, adenocarcinoma histology, and Asian descent 
were prognostic factors favoring a response (Fukuoka 2003; 
Miller 2004). Somatic mutations that led to in-frame dele-
tions and missense substitutions in the ATB-binding pocket 
of EGFR were responsible for this exquisite sensitivity to 
geﬁ  tinib (Sordella 2004; Han 2005; Mitsudomi 2005). We do 
not know the EGFR mutation status in our patient. But given 
her gender, adenocarcinoma histology, lace of a smoking 
history, and Asian decent, she would be likely to have EGFR 
mutations that confer a favorable response to geﬁ  tinib. Fur-
thermore, at standard dose of 250 mg daily or higher, geﬁ  tinib 
has efﬁ  cacy against metastases in the brain parenchyma and 
leptomeninges (Katz 2003; Jackman 2006).
We think that the combination of geﬁ  tinib and high-dose 
fractionated cranial irradiation was responsible for this patient’s 
rapid recovery and complete response in the brain. The neuro-
logical improvement seen in our patient was unlikely a result 
of geﬁ  tinib alone, since her liver and bone metastases had a 
limited response. There is preclinical data to support this notion 
because a combination of geﬁ  tinib and radiation had an additive 
cytotoxic effect on A431 cells (vulvar carcinoma cells that have 
high levels of EGFR) in vitro and a synergistic anti-tumor effect 
on GEO (human colon carcinoma), A549 (human non-small cell 
carcinoma), and MCF-7 (human breast carcinoma) xenografts 
in nude mice (Bianco 2002; Giocanti 2004). Interestingly, there 
was decreased tumor expression of transformation growth fac-
tor α, vascular endothelial growth factor, and basic ﬁ  broblast 
growth factor (Bianco 2002), suggesting mechanisms other than 
inhibition of EGFR signaling may be at work.
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